SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase 1b, Multicenter Study

Overview of attention for article published in Cancer Discovery, October 2018

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news: 21 news outlets
blogs: 1 blog
twitter: 35 X users

patent: 4 patents
facebook: 1 Facebook page
googleplus: 2 Google+ users

Citations

dimensions_citation: 231 Dimensions

Readers on

mendeley: 164 Mendeley

Summary News Blogs X Patents Facebook Google+ Dimensions citations

So far, Altmetric has seen 4 patents that reference this research output.

Complex of beta glucan and nucleic acid with controlled particle diameter

Application KR-20230107833-A

Republic of Korea

DIMERIC CPG OLIGONUCLEOTIDES FOR USE IN MODULATING IMMUNE RESPONSES

Application EP-3966331-A4

European Patent Office

Compositions and methods for treating melanoma

Grant US-11633458-B2

United States of America

COMPLEX OF β-GLUCAN AND NUCLEIC ACID HAVING CONTROLLED PARTICLE SIZE

Application WO-2022102694-A1

World Intellectual Property Organisation (WIPO)

This page shows the most recent patents that mention this research output.

Click here to find out how to access more activity.